Published monthly by WHO, this update contains information on immunisation technology and GAVI, plus news of immunisation activities in countries.

 

Evaluation Advisory Committee Meeting
19-20 January 2012
EAC -2012 -Mtg -1 1




GAVI Alliance Evaluation Advisory Committee Meeting
19-20 January 2012
Geneva, Switzerland


FINAL MINUTES


Introduction and welcome

Finding a quorum of members present, the meeting commenced at 9.00 Geneva
time on 19 January 2012 . Sania Nishtar, Committee Chair , chaired the meeting.

Seth Berkley, CEO of the GAVI Alliance, welcomed the Committee, highlighting the
issues that they would be discussing during this meeting and stressing in particular
their important role in the Fu ll Country Evaluation process. He gave an overview of
the decisions made by the GAVI Alliance Board a t its meeting in November 2011
and indi cated that there are a number of related issues which will be brought to the
EAC in the future.

----- -

1. Chair?s report

1.1 Standing declarations of interest were tabled to the Committee (Doc #1a ).
Alan Hinman indicated that although he did not have a Conflict of Interest he
would recuse himself from the discussion on the CSO Evaluation under
Agenda Item 5 .

1.2 The Committee noted the minutes of its meeting of 13 -14 S eptember 2011 in
Geneva (Doc #1b). The se minutes were approved by n o objection on 12
December 2011.

--- ---

2. Update from the Secretariat


2.1 Peter Hansen, Director of Monitoring & Evaluation , presented information on
the outcome of the GAVI Board meeting held in Dhaka, Bangladesh, in
November 20 11 and an update on monitoring and evaluation activities, in
particular in relation to routin e programme monitoring and targeted studies.

Discussion
 

 

Published monthly by WHO, this update contains information on immunisation technology and GAVI, plus news of immunisation activities in countries.

Board -2011 -Mtg -3-Doc 00b


GAVI Alliance Board Meeting
16 -17 November 2011
Ruposhi Bangla Hotel, Dhaka , Bangladesh

Monday 14 November: Field visits
Tuesday 15 November: Pre -Board meetings
Wednesday 16 November : 9.00 -18.15 (Board meeting Day One)
Thurs day 17 November : 8.00 -18.00 (Board meeting Day Two)
Quorum: 12

Agenda

Pre -Board Field visits ? Monday 14 November 2011
Item Subject Room Schedule

Welcoming coffee with pastries Hotel Lobby 6.00 -6.30
A Board Field Visit to rural c ommunity clinics in the
Sreepur area (lunch included)
6. 30-17 .00
B Visit to Matlab (lunch included ) 6. 30-18 .00
C Field Visit to ICDDR ,B Centre and Hospital 13.00 -18.00

Pre -Board Meetings ? Tues day 1 5 November 2011

Item Subject Room Schedule

Pre -Board meetings
? IFFIm Board Meeting
? Technical briefing
Coffee available
? IFFIm donors meeting
? New Board members meeting hosted by the Chair
? Developing Countries Constituency meeting
? Unaffiliated B oard members briefing
? GAVI Donors meeting
? Unaffiliated recruitment Committee meeting
? Chair?s individual meetings with Committee Chairs

Palash
Chameli

Bakul
Palash
Palash
Chameli
Bakul
Chameli


8.00 -9.45
9.00 -11.00
9.30 -11.45
10.00 -11.30
10.00 -11.00
11.00 -12.30
11.30 -12.30
11.30 -13.30
12.30 -13.00
TBD

Lunch for all partic ipants Marble room 13.00 -14.00
? Executive Committee
? Governance Committee
Coffee
? Closed Executive Session
Ballroom
Palash
Ballroom Foyer
Ballroom
14.30 -15.30
15.30 -16.30
16.00 -16.30
16.30 -18.30


Inauguration Ceremony
Cultural Programme with non -alcoholic refreshments
Dinner hosted by Bangladeshi P rime Minister
Winter Garden
Winter Garden
Winter Garden
19.00
19.30
20.0 0

1


Report to the
GAVI Alliance Board

Board -2011 -Mtg -3-Doc 02
16 -17 November 2011
Report of the Chief Executive Officer


9 November 2011
Dear Board Members,

It is a great pleasure to provide you with this report, which combined with my board
presentation, provide my perspective on the first GAVI Board meeting I will attend as
CEO, as well as my first 100 days on the job.
I am grateful to the Government of Ba ngladesh for hosting this Board meeting.
Around the meeting we will have the opportunity to see some of the Government?s
achievements in improving the health of the people of Bangladesh. I would
particularly like to highlight and thank Faruque Ahmed as a former Board member
and Director of the Health Program me of the Bangladesh Rural Advancement
Committee (BRAC) which represents one of the best examples of the power of civil
socie ty in development in Bangladesh and around the world.
It is five months sinc e GAVI?s last Board meeting, and three months since I became
CEO. Some of the papers that have been provided for the Board and the decisions
that the Board will be invited to take are the result of processes that began many
months before I became CEO, an d so the perspective I offer here and at the Board
meeting is in some respects still one of an outsider. Of course, I am fully engaged
and so this is really the last time I will be able to say this?
GAVI has a strong business model, with a relatively smal l secretariat, and a large
well -functioning Alliance, drawing on the strengths of each of the partners. Our
model allows us to pool vaccine demand from countries and funding from donors, to
create a significant market for vaccines appropriate for people l iving in the poorest
countries.
This model has achieved some powerful results. Since GAVI?s inception in 2000,
WHO now estimates that the Alliance has helped countries prevent more than 5.5
million future deaths by immunizing 326 million additional chil dren against hepatitis B,
Haemophilus influenza type b (Hib), measles, pertussis, pneumococcal disease,
polio, rotavirus diarrhoea and yellow fever.
I am particularly grateful to WHO fo r providing these figures. W e are also working
with our partners to strengthen the methodology behind them and the way we report
results. An additional important challenge will be to capture our collective impact on
morbidity. For many vaccines, Meningococcal A , Polio, and Rubella being good
examples, the largest effects will be in reducing morbidity. We all know we are
making a big difference in this area but we do not have an agreed way of measuring
it.

Report to the
GAVI Alliance Board


Board-2011-Mtg -3-Doc 03a
16 -17 November 2011
Subject: Accelerated Vaccine Introduction ? progress report
Report of: Nina Schwalbe, MD, Policy and Performance
Authored by: Jon Pearman, Director AVI, Policy and Performance,
Johanna Fihman, with input from AVI management team
Agenda item: 03a
Category: For Guidance/Discussion
Strategic goal: SG1 - Vaccines & SG4 - Market shaping


Section A: Overview
1. Purpose of the r eport

1.1 The purpose of this report is to provide a summary on the progress of the
Accelerated Vaccine Introduction (AVI) initiative and review ongoing
challenges to building a successful platform for future new vaccine introduction
going forward.

2. Recommendations

2.1 For information only.

3. Executive Summary

3.1 With regard to pneumococcal vaccines, five countries have introduced s ince
the AVI Board update in July, making a total of 16 countries forecasted to have
introduced by year end. T he demand for pneumo vaccines has increased with
the approval of an addit ional 18 countries by the Executive Committee in
September . In spite of new supply agreements signed under the AMC, vaccine
supply has become even tighter in 2012 and 2013.

3.2 With regard to rotavirus vaccines, in July Sudan became the first country
outside Latin America to launch. The demand for rota vaccines has increased
with approval of an additional 14 countries by the Executive Committee in
September and there are forecast to be 30 countries introduc ing in 2012 - 13
time -frame . Award notification has been issued for longer term contracts for
rota. There is sufficient supply over the long -term to meet demand, with the
exception of 2013 where there will be supply constraints.

3.3 The GAVI Secretariat , with support from the AVI partners , worked on the
development of implementation plans for new vaccines ( agenda item 5 ).

1


Report to the
GAVI Alliance Board

Board -2011 -Mtg -3-Doc 03b
16 -17 November 2011
Subject : Country Programmes Update
Report of: Mercy Ahun, MD, Programme Delivery
Authored by: Paul Kelly , Director, Country Programme s
Bakhuti Shengelia, Director, Country Grants and Renewals
Agenda item : 03b
Category: For Decision
Strategic goal : SG1 - Vaccines, SG2 - Health systems, SG3 - Financing

Section A: Overview

1. Purpose of the repor t

1.1 The purpose of this report is to update the Board on : the implementation and
performance o f country programmes ; the outcome of the work of the Large Cou ntry Task
Team ; and on the possibility that the Democratic Republic of Congo could default on co -
financing commitments . The report outlines achievements and challenges against three
of the four GAVI Alliance strategic goals:
? SG1 ? Accelerate use of underu sed and new vaccines;
? SG2 ? Contribute to strengthening the capacity of integrated health systems to
deliver immunisation;
? SG3 ? Increase the predictability of global financing and improve the sustainability of
national financing for immunisation.

2. Recomm endations

2.1 The Secretariat recommends that the Board :
? Approve the continuation of existing vaccine support for Pentavalent and Yellow
Fever vaccines for DRC in 2012, in the event that the country is unable to pay its
2010 co -financing arrears for these va ccines by the end of 2011.
2.2 The Board may also wish to note that, with respect to India and Nigeria, the Policy and
Programme Committee agreed in September that the two countries need a tailored
approach for GAVI support and asked the Secretariat to work wi th the se countries and
partners to develop a country strategy .

3. Executive summary

3.1 Countries continue to make progress towards the objectives of the Alliance?s strategic
goals. Based on WHO/UNICEF estimates , average DTP3 coverage increased from 73%
to 78% in GAVI eligible countries from 2009 to 2010. The number of countries with at
least 90% coverage increased by 27% (from 26 in 2009 to 33 in 2010). However, the
preliminary Ethiopia Demographic & Health Survey 2011 report highlights ongoing

1


Report to the
GAVI Alliance Board
Board -2011 -Mtg -3-Doc 05
16 -17 November 2011


Subject : Updated long term financial forecast
Report of: Barry Greene, MD, Finance and Operations
Authored by: Tony Dutson, Senior Director, Finance & Chief
Accounting Officer
Agenda item : 05
Category: For Guidance/Discussion
Strategic goal : Alliance operations


Section A: Overview

1. Purpose of the repor t

1.1 This paper informs the Board of the updated GAVI financial forecast for 2011 -
20 16 (Version 4.0Fb ).


2. Recommendations

2.1 For information only.

3. Executive summary

3.1 Th e updated GAVI financial forecast incorporates the latest demand estimates
and funding decisions taken to date 1. The level of resources reflects the results
of the 13 June 2011 Pledging C onference and subsequent follow -up with
donors , and foreign exchange rates at 30 September 2011 .

3.2 The financial forecast has been extended through 2016 to provide visibility
through the next five calendar years, which is required by the Programme
Funding Policy for the endorsement and approval of new programmes in 2011.

3.3 Expenditure of US $ 9.3 billion is forecast for 2011 -201 6. This includes US$
7.7 billion for the period 2011 -2015, which is larger than the February 2011
estimate of US$ 6.8 billion (for 2011 -2015) mainly because of the magnitude of
demand from the new proposals recommended by the IRC in July 2011. The
total of US$ 9.3 billion compris es :
1 Including the funding decisions that the Executive Committee will consider for approval in November
2011 .

1


Report to the
GAVI Alliance Board

Board -2011 -Mtg -3-Doc 06
16 -17 November 2011
Subject : Ne xt steps on new vaccine windows:
HPV, JE, Rubella and Typhoid
Report of: Nina Schwalbe, MD, Policy and Performance
Authored by:
Jon Pearman, Director, Katie Moore, Senior
Manager, Accelerated Vaccine Introduction (AVI)
initiative
Agenda item : 06
Category: For Decision
Strategic goal : SG1 - Underused and new vaccines


Section A: Overview
1. Purpose of the repor t
1.1 The GAVI Alliance Board is requested to approve next steps for GAVI?s
vaccine portfolio and specific implementation strategies for human papilloma
virus (HPV) and rubella vaccines .

2. Recommendations
2.1 The GAVI Alliance Programme and Policy Committee (PPC) recommend ed
the GAVI B oard to:
a) Open a funding window for HPV and rubella vaccines such that the GAVI
Secretariat can invite country proposals for support in 2012 ;1
b) Request the Secretariat to work with technical partners to develop an HPV
pilot programme following the Board meeting in November 2011;
c) Note that JE is a critically important vaccine , particularly for South East
Asia. GAVI should consider opening a window once an appropriate vaccine
is prequalified. Continued efforts are needed on surveillance ;
d) Not to revisit its previous decision on typhoid noting that the Alliance looks
forward to the development of an appropriate conjugate vaccine.

1 September application round